Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 83, Issue 2, Pages 269-293
Publisher
Wiley
Online
2016-08-17
DOI
10.1111/bcp.13095
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals
- (2015) Rebecca Cope et al. AIDS PATIENT CARE AND STDS
- Prevalence of Drug–Drug Interactions upon Addition of Simeprevir- or Sofosbuvir-Containing Treatment to Medication Profiles of Patients with HIV and Hepatitis C Coinfection
- (2015) Nimish Patel et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies
- (2015) K. Deterding et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir
- (2015) P. Badri et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
- (2015) Prajakta S. Badri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment
- (2015) Tushar Garimella et al. ANTIVIRAL THERAPY
- The Concise Guide to PHARMACOLOGY 2015/16: Transporters
- (2015) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Concise Guide to PHARMACOLOGY 2015/16: Enzymes
- (2015) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects
- (2015) Marc Bifano et al. CLINICAL DRUG INVESTIGATION
- Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
- (2015) Sivi Ouwerkerk-Mahadevan et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
- (2015) Brian J. Kirby et al. CLINICAL PHARMACOKINETICS
- Drug interactions with new hepatitis C oral drugs
- (2015) Vincent Soriano et al. Expert Opinion on Drug Metabolism & Toxicology
- Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned
- (2015) David J. Back et al. GASTROENTEROLOGY
- The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related Child's Class A Cirrhosis
- (2015) Brian L. Pearlman et al. GASTROENTEROLOGY
- Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
- (2015) Michael Charlton et al. GASTROENTEROLOGY
- A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection
- (2015) Travis B. Dick et al. HEPATOLOGY
- Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update
- (2015) Jose M. Miro et al. JOURNAL OF HEPATOLOGY
- Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment
- (2015) Amit Khatri et al. JOURNAL OF HEPATOLOGY
- Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease
- (2015) Bhamidimarri Kalyan Ram et al. JOURNAL OF HEPATOLOGY
- Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
- (2015) Rajeev M. Menon et al. JOURNAL OF HEPATOLOGY
- Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
- (2015) Jacob Lalezari et al. JOURNAL OF HEPATOLOGY
- Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting
- (2015) Christoph Höner zu Siederdissen et al. LIVER INTERNATIONAL
- A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease
- (2015) Anna Maruyama et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
- (2015) Christopher Southan et al. NUCLEIC ACIDS RESEARCH
- Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
- (2015) Isabelle Poizot-Martin et al. PLoS One
- Hepatitis C virus and liver transplantation: where do we stand?
- (2015) Patrizia Burra et al. TRANSPLANT INTERNATIONAL
- Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
- (2015) Sivi Ouwerkerk-Mahadevan et al. Drugs in research & development
- The Rapid Evolution of Treatment Strategies for Hepatitis C
- (2014) Andrew J Muir AMERICAN JOURNAL OF GASTROENTEROLOGY
- Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides
- (2014) Tomomi Furihata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting
- (2014) I. Campos-Varela et al. CLINICAL INFECTIOUS DISEASES
- Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations
- (2014) Clara T. M. M. de Kanter et al. CLINICAL PHARMACOKINETICS
- Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
- (2014) Adriano M. Pellicelli et al. DIGESTIVE AND LIVER DISEASE
- Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?
- (2014) Sarah Talavera Pons et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database
- (2014) Julie C. Lauffenburger et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-Uninfected female subjects
- (2014) P. German et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study
- (2014) Tomohiro Tanaka et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation
- (2014) Martina Gambato et al. JOURNAL OF HEPATOLOGY
- Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals
- (2014) Audrey Coilly et al. LIVER INTERNATIONAL
- Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients
- (2014) Joy Peter et al. LIVER INTERNATIONAL
- Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation
- (2014) Yoshihide Ueda et al. TRANSPLANT INTERNATIONAL
- The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C
- (2013) B. Maasoumy et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C
- (2013) R. J. Fontana et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection
- (2013) Drosos E. Karageorgopoulos et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Drug–drug interactions during antiviral therapy for chronic hepatitis C
- (2013) Jennifer J. Kiser et al. Nature Reviews Gastroenterology & Hepatology
- Pharmacokinetics of new oral hepatitis C antiviral drugs
- (2012) Eugenia Vispo et al. Expert Opinion on Drug Metabolism & Toxicology
- Mécanismes des interactions médicamenteuses d’origine pharmacocinétique
- (2009) D. Levêque et al. REVUE DE MEDECINE INTERNE
- The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters
- (2009) Olena Kis et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Induction Effects of Ritonavir: Implications for Drug Interactions
- (2008) Michelle M Foisy et al. ANNALS OF PHARMACOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now